Dynamic Serial Cytokine Measurements During Intravenous Ca-DTPA Chelation in Gadolinium Deposition Disease and Gadolinium Storage Condition: A Pilot Study.
Journal
Investigative radiology
ISSN: 1536-0210
Titre abrégé: Invest Radiol
Pays: United States
ID NLM: 0045377
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
pubmed:
14
6
2021
medline:
7
1
2022
entrez:
13
6
2021
Statut:
ppublish
Résumé
The aim of this study was to investigate the feasibility of measuring early changes in serum cytokine levels after intravenous diethylenetriaminepentaacetic acid (Ca-DTPA) chelation in patients manifesting either gadolinium deposition disease (GDD) or gadolinium storage condition (GSC) and the possible usefulness of this method in further research. Four patients with recent-onset GDD (≤1 year) and 2 patients with long-standing GSC (4 and 9 years) underwent chelation with intravenous bolus administration of Ca-DTPA. Multiple blood draws were performed to measure serum cytokines: at T = 0 (before Ca-DTPA injection) and 1, 5, 10, 30, 60 minutes, and 24 hours after Ca-DTPA injection. Patients rated the severity of GDD symptom flare at 24 hours. The 24-hour urine Gd amounts were measured prechelation and for the 24 hours after chelation. Serum samples were analyzed blind to whether patients had GDD or GSC but with knowledge of the time points characterizing each sample. Urine samples for both GDD and GSC patients showed increases in Gd postchelation. All GDD patients experienced flare reactions postchelation; the 2 GSC patients did not. Two cytokines, EGF and sCD40L, peaked at 30 minutes postchelation in at least 4 of the 6 participants. Three cytokines, ENA78/CXCL5, EOTAXIN/CCL11, and LEPTIN, peaked at 24 hours in at least 4 of the 6 participants. Two participants were high outliers for a large number of cytokines across time points. No clear distinction between GDD and GSC was apparent from the cytokine patterns, although differences were present. This pilot study describes precise temporal resolution (in the range of minutes) after a cytokine-inciting event. Select cytokines exhibited peak values at different time points. At this preliminary stage of investigation, peak cytokine release seems to reflect the amount of Gd mobilized rather than the severity of the patient symptomatic reaction. Too few subjects were studied to support statistical analysis between GDD and GSC groups, although differences were observed through visual data analysis.
Identifiants
pubmed: 34120127
doi: 10.1097/RLI.0000000000000803
pii: 00004424-202201000-00008
pmc: PMC8664920
mid: NIHMS1744450
doi:
Substances chimiques
Contrast Media
0
Cytokines
0
Organometallic Compounds
0
Pentetic Acid
7A314HQM0I
Gadolinium
AU0V1LM3JT
Gadolinium DTPA
K2I13DR72L
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
71-76Subventions
Organisme : NIAID NIH HHS
ID : U19 AI057229
Pays : United States
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Gibby WA, Gibby KA, Gibby WA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol . 2004;39:138–142.
White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol . 2006;41:272–278.
Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, et al. Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics . 2009;1:479–488.
Kanda T, Fukusato T, Matsuda M, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology . 2015;276:228–232.
Tedeschi E, Caranci F, Giordano F, et al. Gadolinium retention in the body: what we know and what we can do. Radiol Med . 2017;122:589–600.
Stanescu AL, Shaw DW, Murata N, et al. Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation. Pediatr Radiol . 2020;50:388–396.
Murata N, Murata K, Gonzalez-Cuyar LF, et al. Gadolinium tissue deposition in brain and bone. Magn Reson Imaging . 2016;34:1359–1365.
Semelka RC, Ramalho M, AlObaidy M, et al. Gadolinium in humans: a family of disorders. AJR Am J Roentgenol . 2016;207:229–233.
Wermuth PJ, Del Galdo F, Jiménez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum . 2009;60:1508–1518.
Wermuth PJ, Jimenez SA. Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents. Clin Exp Immunol . 2014;175:113–125.
Weng TI, Chen HJ, Lu CW, et al. Exposure of macrophages to low-dose gadolinium-based contrast medium: impact on oxidative stress and cytokines production. Contrast Media Mol Imaging . 2018;2018:3535769.
Steger-Hartmann T, Raschke M, Riefke B, et al. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis—a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol . 2009;61:537–552.
Bower DV, Richter JK, von Tengg-Kobligk H, et al. Gadolinium-based MRI contrast agents induce mitochondrial toxicity and cell death in human neurons, and toxicity increases with reduced kinetic stability of the agent. Invest Radiol . 2019;54:453–463.
Ramalho J, Semelka RC, Ramalho M, et al. Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol . 2016;37:1192–1198.
Alkhunizi SM, Fakhoury M, Abou-Kheir W, et al. Gadolinium retention in the central and peripheral nervous system: implications for pain, cognition, and neurogenesis. Radiology . 2020;297:407–416.
Schäfers M, Svensson CI, Sommer C, et al. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci . 2003;23:2517–2521.
Schäfers M, Sorkin L. Effect of cytokines on neuronal excitability. Neurosci Lett . 2008;437:188–193.
Ozaktay AC, Kallakuri S, Takebayashi T, et al. Effects of interleukin-1 beta, interleukin-6, and tumor necrosis factor on sensitivity of dorsal root ganglion and peripheral receptive fields in rats. Eur Spine J . 2006;15:1529–1537.
DeLeo JA, Colburn RW, Nichols M, et al. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res . 1996;16:695–700.
Semelka R, Ramalho M. Physicians with self-diagnosed gadolinium deposition disease: a case series. http://www.rb.org.br/detalhe_aop.asp?id=3328 .
Maecker HT, Wang W, Rosenberg-Hasson Y, et al. An initial investigation of serum cytokine levels in patients with gadolinium retention. Radiol Bras . 2020;53:306–313.
Maecker HT, Siebert JC, Rosenberg-Hasson Y, et al. Acute chelation therapy-associated changes in urine gadolinium, self-reported flare severity, and serum cytokines in gadolinium deposition disease. Invest Radiol . 2021;56:374–384.
Orange DE, Yao V, Sawicka K, et al. RNA identification of PRIME cells predicting rheumatoid arthritis flares. N Engl J Med . 2020;383:218–228.
Anon. 7.1.6. What are outliers in the data? Available at: https://www.itl.nist.gov/div898/handbook/prc/section1/prc16.htm . Accessed March 17, 2021.
Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med . 2020;383:2652–2664.